Category: Clinical Trials

Research
Groundbreaking News for ATTR Cardiac Amyloidosis Community
Yesterday was a big milestone for the ATTR amyloidosis community. Pfizer announced the results from their phase III ATTR-ACT study of tafamidis for patients with cardiac ATTR amyloidosis. The results demonstrated a statistically significant reduction in the numbers of deaths...
Read More
My Amyloidosis Pathfinder
ARC Launches Version Two of Clinical Trial Tool
The Amyloidosis Research Consortium (ARC) recently launched the latest version of the My Amyloidosis Pathfinder (MAP) tool. This groundbreaking tool was created to help connect amyloidosis patients to appropriate treatment centers and clinical trials for their disease. The latest updates...
Read More
Gene Silencing Holds Promise for Treating Hereditary ATTR Amyloidosis
A novel therapeutic approach which exploits the normal biological process of gene silencing, or RNA interference (RNAi), is continuing to show promise as a potential treatment for hereditary ATTR (hATTR) amyloidosis. Results presented recently at the 1st European ATTR Amyloidosis...
Read More
Coming Together to Make a Difference
ARC held its biannual Industry Advisory Council meeting in Boston on March 27th, 2017. The day-long meeting was attended by representatives from pharmaceutical and biotech companies developing new treatments for amyloidosis.  This provided a unique opportunity for these companies to...
Read More
Clinical Trials Update from Ionis Pharmaceuticals
The Phase 3 outcome study of CARDIO-TTR, evaluating patients with TTR amyloid cardiomyopathy through the IONIS-TTRRx program will not be initiated. The other IONIS-TTRRx studies are continuing and include the NEURO-TTR Phase 3 study and Dr. Merrill Benson’s investigator-initiated Phase...
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
22 (G1) FORTH STREET, EDINBURGH, UK EH1 3LH | +44 (0) 131 550 3866
arc@arci.org

ARC is a 501(c)(3) nonprofit organization